Abstracts tagged "pregnancy"

Abstract Number: 1075 • 2019 ACR/ARP Annual Meeting
The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases
Lena Sabih¹, Jennifer Strouse ¹, Nichole Nidey ², Gretchen Bandoli ³, Rebecca Baer ⁴, Sky Feuer ⁵, Laura Jelliffe-Pawlowski ⁵, Christina Chambers ⁶, Kelli Ryckman ² and Namrata Singh ⁷, ¹University of Iowa Hospitals and Clinics, Iowa City, ²UIOWA, Iowa City, ³University of California, San Diego, La Jolla, ⁴UCSD, La Jolla, ⁵UCSF, San Francisco, ⁶UCSD, San Diego, ⁷University of Iowa, Iowa City
Background/Purpose: Autoimmune rheumatic diseases (ARDs) are associated with adverse pregnancy outcomes (APOs). There are only a small number of studies that have looked at the…
Abstract Number: 2297 • 2019 ACR/ARP Annual Meeting
Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate’s Immune System
Yiyi Luo ¹, Andrea Pluma ², Raul Castellanos-Moreira³, Estefania Moreno ⁴, Nuria Baños ⁵, Sebastian DC Rodriguez-Garcia ⁶, Angela Deyà-Martínez ¹, Ana Pilar Garcia-Garcia ¹, Mireia Torres ⁷, Dolors Grados ⁸, Manel Casellas ⁹, Manel Juan ¹, Ana Esteve-Sole ¹ and Laia Alsina ¹⁰, ¹Immunology Department. Center for Biomedical Diagnosis. Hospital Clínic of Barcelona IDIBAPS. Barcelona University. Barcelona. Functional unit of Clinical Immunology HSJD-HCP.Universidad de Barcelona. Pediatric Investigation Institute SJD, Barcelona, Spain, ²Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁴Rheumatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁵Matern-Infantile Department, Hospital Clínic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁶Arthritis Unit. Rheumatology Department. Hospital Clinic of Barcelona. Barcelona. Spain, Barcelona, Spain, ⁷Neonatology Department. Vall d'Hebron University Hospital, Barcelona, Spain, Barcelona, Spain, ⁸Hospital d'Igualada, Barcelona, ⁹Hospital Universitari Vall d'Hebron, Barcelona, ¹⁰Hospital Sant Joan de Déu, Barcelona, Spain
Background/Purpose: Up to half of pregnant patients with rheumatic diseases experience disease activity which can increase the risk of pregnancy complications and poor disease outcomes. Treatment…
Abstract Number: 1273 • 2019 ACR/ARP Annual Meeting
Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study
DIANA PRIETO- PENA¹, Vanesa Calvo Río ², Mónica Calderón-Goercke ³, Olga Maíz Alonso ⁴, JR Jimenez-Aberasturi ⁵, Raul Veroz ⁶, Maria Soledad Blanco ⁷, José Manuel Santos ⁸, Francisco Navarro ⁹, Adela Gallego ¹⁰, Rosalia Demetrio ¹¹, Victor Manuel Martínez Taboada ¹¹, Miguel Angel González-Gay ¹² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴H. Donostia, San Sebastián, Spain, ⁵HU Araba, Vitoria, Spain, ⁶H. Mérida, Merida, Spain, ⁷H. Galdakano, Bilbao, Spain, ⁸H. Río Hortega, Valladolid, Spain, ⁹H.Elche, Alicante, Spain, ¹⁰H. Badajoz, Badajoz, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Uveitis often occur in women who are in their reproductive years. The management of uveitis during pregnancy is a challenge, making the physician to…
Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Peter Izmirly¹, Mimi Kim ², Nathalie Costedoat-Chalumeau ³, Deborah Friedman ⁴, Amit Saxena ⁵, Joshua Copel ⁶, Rebecca Cohen ¹, Mala Masson ¹, Tishaun Middleton ¹, Kimberly Robins ¹, Robert Clancy ¹ and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Albert Einstein College of Medicine, Bronx, NY, ³Cochin University Hospital, Paris, France, ⁴New York Medical College, Valhalla, ⁵New York University School of Medicine, New York, NY, ⁶Yale School of Medicine, New Haven
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…
Abstract Number: 1896 • 2019 ACR/ARP Annual Meeting
Breastfeeding in Women with Rheumatic Diseases
Naira Ikram¹, Amanda Eudy ¹ and Megan Clowse ¹, ¹Duke University, Durham
Background/Purpose: For many women, breastfeeding is a central aspect of motherhood, but many worry that their rheumatic disease or treatment will interfere. Fortunately, most anti-rheumatic…
Abstract Number: 1899 • 2019 ACR/ARP Annual Meeting
sFlt-1, PlGF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia
Guilherme De Jesus¹, Marcela Lacerda ¹, Bruna Rodrigues ¹, Flavia dos Santos ¹, Adriana Nascimento ¹, Luis Cristóvão Porto ¹, Nilson Ramires de Jesús ¹, Roger Levy ² and Evandro Klumb ¹, ¹Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ²GlaxoSmithKline, Upper Providence, PA
Background/Purpose: Pregnancy in patients with SLE is associated with significant morbidity and mortality. SLE activity during pregnancy, specifically nephritis, makes the differential diagnosis with preeclampsia…
Abstract Number: 1900 • 2019 ACR/ARP Annual Meeting
Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies
Kimberly Robins ¹, Rohit Bhan¹, Catherine Trad ¹, Rebecca Cohen ¹, Miao Chang ¹, Benjamin Wainwright ¹, Mala Masson ¹, Shilpi Mehta-Lee ¹, Peter Izmirly ¹, Robert Clancy ¹, Bettina Cuneo ² and Jill Buyon ¹, ¹NYU School of Medicine, New York, ²Children's Hospital Colorado, Aurora
Background/Purpose: Pregnancy counseling of all anti-Ro positive women includes advice regarding the development of congenital heart block (CHB), albeit the risk is only 2% for…
Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…
Abstract Number: 1938 • 2019 ACR/ARP Annual Meeting
The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study
Amogh Pathi ¹, Mette Smed ², Lior Pachter ³, Elizabeth Purdom ⁴, Matthew Wright ⁵, Nicholas Jewell ⁴, J. Lee Nelson ⁶, Jørn Olsen ⁷, Merete Lund Hetland ⁸, Vibeke Zoffmann ⁹ and Damini Jawaheer¹⁰, ¹UCSF Benioff Children's Hospital Oakland, Oakland, ²Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ³Caltech, Pasadena, ⁴University of California Berkeley, Berkeley, ⁵UCSF Benioff Children's Hopsital Oakland, Oakland, ⁶Fred Hutchinson Cancer Research Center, Seattle, ⁷Aarhus University Hospital, Aarhus, Denmark, ⁸DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁹Juliane Marie Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, ¹⁰UCSF Benioff Children's Hospital Oakland, Oakland, CA
Background/Purpose: Pregnancy is known to induce a natural improvement of Rheumatoid Arthritis (RA) symptoms in 50-75% of patients as gestation progresses. However, the underlying mechanisms…
Abstract Number: 2273 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infections in Offspring According to TNFi Subtypes
Evelyne Vinet¹, Yvan St-Pierre ¹, Cristiano S. Moura ¹, Jeffrey Curtis ² and Sasha Bernatsky ³, ¹McGill University Health Centre, Montreal, QC, Canada, ²University of Alabama at Birmingham, Birmingham, AL, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: TNFi subtypes have differential placental transfer, with some reaching higher fetal than maternal blood levels. Thus, certain TNFi subtypes could cause immunosuppression in the offspring.…
Abstract Number: 2276 • 2019 ACR/ARP Annual Meeting
Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach
Ravyn Njagu¹, Amanda Eudy ², Amanda Snyderman ¹, Lisa Criscione-Schreiber ² and Megan Clowse ², ¹Duke University, Durham, NC, ²Duke University, Durham
Background/Purpose: While centers have worked to optimize lupus pregnancy outcomes, additional efforts are required to have a broader impact on lupus pregnancy outcomes. The goal…
Abstract Number: 2277 • 2019 ACR/ARP Annual Meeting
Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists
Tierney Wolgemuth ¹, Mehret Birru Talabi ¹, Alaina Chodoff ², Sonya Borrero ³ and Mehret Talabi¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC, Pittsburgh, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Women with rheumatic diseases may be at greater risk for adverse maternal, perinatal, and pregnancy outcomes. The American College of Rheumatology recommends that female…
Abstract Number: 2279 • 2019 ACR/ARP Annual Meeting
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study
Isabell Haase¹, Susanna Spaethling-Mestekemper ², Ralph Brinks ¹, Matthias Schneider ³ and Rebecca Fischer-Betz ³, ¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ²Rheumapraxis, Munich, Germany, ³Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: Women with active Rheumatoid Arthritis (RA) are more prone to relapses and complications during pregnancy. The potential risks of disease activation and treatment during…
Abstract Number: 2287 • 2019 ACR/ARP Annual Meeting
Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion
Hindi Stohl ¹, Ning Yu ² and William Stohl², ¹Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Immunologic, angiogenic, and anti-angiogenic factors have been associated with spontaneous abortion (SAB), yet early identification of those pregnant women who ultimately undergo SAB remains…
Abstract Number: 2288 • 2019 ACR/ARP Annual Meeting
Pregnancy Outcomes in Women Exposed to Golimumab
Suzan Esslinger¹, Susan Gabriel ², Marijo Otero-Lobato ³, Michael Clark ⁴, Pamela Sheridan ⁴ and Anja Geldhof ⁵, ¹Janssen Biologics BV, Leiden, Netherlands, ²Janssen Rearch & Development, LLC, Horsham, PA, ³Janssen Biologics BV, Leiden, Zuid-Holland, Netherlands, ⁴Janssen Research & Development, LLC, Horsham, PA, ⁵Janssen Research & Development, LLC, Leiden, Netherlands
Background/Purpose: Rheumatologic disorders and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].